Medical Health & Life Science Research News

Integrin alpha V pipeline review H1 2017 study with competitive landscape, market insights & forecast to 2022 made available by top research firm

Integrin alpha V pipeline review H1 2017 study with competitive landscape, market insights & forecast to 2022 made available by top research firm

HTF Market Intelligence released a new research report of 74 pages on title 'Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017’ with detailed analysis, forecast and strategies. The study covers important players such as Biogen Inc, BioMAS Ltd, Factor Therapeutics Ltd, MedImmune LLC.

- Advertisement -
- Membership expired -

Summary

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2017

Request a sample report @ www.htfmarketreport.com/sample-rep…-integrin-alpha-v

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF.

The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits.

- Advertisement -
- Membership expired -
The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase II and Preclinical stages are 6 and 13 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Respiratory, Gastrointestinal, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease and Toxicology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Idiopathic Pulmonary Fibrosis, Diabetic Retinopathy, Fibrosis, Glioblastoma Multiforme (GBM), Pancreatic Cancer, Cardiovascular Disease, Chemotherapy Effects, Diabetic Macular Edema, Diabetic Nephropathy, Genital Warts (Condylomata Acuminata), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Liver Fibrosis, Malabsorption Syndrome, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease) and Venous Leg Ulcers (Crural ulcer).

The latest report Integrin Alpha V - Pipeline Review, H1 2017, outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Companies Mentioned in the Report

Biogen Inc

BioMAS Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics

Access this report @ www.htfmarketreport.com/buy-now?fo…amp;report=498339

Reasons to access

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get report @ www.htfmarketreport.com/request-di…-integrin-alpha-v

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development

Biogen Inc

BioMAS Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/49…-integrin-alpha-v

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany profile: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...

For more information:

Make an Inquiry about this report HERE!
  • www.htfmarketreport.com
  • www.htfmarketreport.com/sample-rep…-integrin-alpha-v
  • www.htfmarketreport.com/buy-now?fo…amp;report=498339
  • www.htfmarketreport.com/request-di…-integrin-alpha-v
  • www.htfmarketreport.com/reports/49…-integrin-alpha-v